GLP-1 RAs ameliorate the glycaemic profile in patients with T2DM by increasing the secretion of insulin and synthesis of pancreatic islet cells, in parallel with a decrease in glucagon secretion and β-cell apoptosis [17,18,19,20,34]. Here, INS is linked to type 2 diabetes mellitus.